Appendix 17b: combination therapy forest plots

The forest plots for combined psychological-pharmacological treatments are referenced 'Combo xx.xx' in the evidence profiles (appendix 18) and summary evidence profiles in the chapters.

Combo 01.01 aggression measures 2
Combo 02.01 anger measures 2
Combo 03.01 anxiety measures 2
Combo 04.01 depression measures (self-rated) 3
Combo 04.02 depression measures (clinician-rated) 3
Combo 05.01 global functioning measures 3
Combo 06.01 quality of life measures 4
Combo 07.01 self-harm/suicidality 4
Combo 08.01 service use measures 5
Combo 09.01 antidepressants: leaving treatment early for any reason 5
Combo 09.02 antipsychotics: leaving treatment early for any reason 5
Combo 10.01 antidepressants: leaving treatment early due to side-effects 6
Combo 10.02 antipsychotics: leaving treatment early due to side-effects 6
Combo 11.01 antidepressants: number of participants reporting side-effects 6
Combo 11.02 antipsychotics: number of participants reporting side-effects 7
Combo 12.01 antipsychotics: weight change 7
Combo 13.01 fluoxetine + IPT versus fluoxetine: efficacy measures 7
Combo 13.02 fluoxetine + IPT versus fluoxetine: quality of life measures 8
Combo 13.03 fluoxetine + IPT versus fluoxetine: acceptability and tolerability measures 8
Combo 14.01 fluoxetine + IPT versus fluoxetine + CT: efficacy measures 9
Combo 14.02 fluoxetine + IPT versus fluoxetine + CT: quality of life measures 9
Combo 14.03 fluoxetine + IPT versus fluoxetine + CT: acceptability and tolerability 10
Combo 15.01 fluoxetine + DBT versus placebo: efficacy measures 10
Combo 15.02 fluoxetine + DBT versus placebo: quality of life measures 11
Combo 15.03 fluoxetine + DBT versus placebo: acceptability and tolerability 11
Combo 16.01 olanzapine + DBT versus placebo: efficacy measures 12
Combo 16.02 olanzapine + DBT versus placebo: service use measures 12
Combo 16.03 olanzapine + DBT versus placebo: acceptability and tolerability measures 12
Combo 16.04 olanzapine + DBT versus placebo: side-effects 14

Combo 01.01 aggression measures

Review: BPD combination pharmacology-psychology
Comparison: 01 Aggression measures
Outcome: 01 Clinician-rated measures

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine + DBT vs placebo + DBT: OAS-M - aggression subscale (12 weeks)						
Simpson 2004 Flx+DBT	9	2.56(3.81)	11	7.45(10.05)		-0.59 [-1.50, 0.31]
Subtotal (95% CI)	9		11			-0.59 [-1.50, 0.31]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.28 (P = 0.20)						

Combo 02.01 anger measures

Review: BPD combination pharmacology-psychology
Comparison: 02 Anger measures
Outcome: 01 STAXI - total (12 weeks)

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine + DBT vs placebo + DBT						
Simpson 2004 Flx+DBT	9	20.56(12.19)	11	27.64(12.36)		-0.55 [-1.45, 0.35]
Subtotal (95% CI)	9		11			-0.55 [-1.45, 0.35]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.20 (P = 0.23)						



Combo 03.01 anxiety measures

Review: BPD combination pharmacology-psychology
Comparison: 03 Anxiety measures
Outcome: 01 Clinician-rated measures (endpoint)

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine + IPT vs fluoxetine: HARS (24 weeks)						
Bellino2004 Flx+IPT	16	11.00(4.40)	16	10.20(3.10)		0.20 [-0.49, 0.90]
Subtotal (95% CI)	16		16			0.20 [-0.49, 0.90]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.58 (P = 0.56)						
02 Fluoxetine + IPT vs fluoxetine + CT: HARS (24 weeks)						
Bellino2007 Flx+IPT	14	13.70(2.80)	12	12.50(1.10)		0.53 [-0.26, 1.32]
Subtotal (95% CI)	14		12			0.53 [-0.26, 1.32]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.32 (P = 0.19)						
03 Olanzapine + DBT vs placebo + DBT: HARS (12 weeks)						
Soler2005 Olz+DBT	30	18.43(5.94)	30	19.93(6.87)		-0.23 [-0.74, 0.28]
Subtotal (95% CI)	30		30			-0.23 [-0.74, 0.28]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.89 (P = 0.37)						
04 Fluoxetine + DBT vs placebo + DBT: STAI (12 weeks)						
Simpson 2004 Flx+DBT	9	101.33(38.06)	11	96.18(28.83)		0.15 [-0.73, 1.03]
Subtotal (95% CI)	9		11			0.15 [-0.73, 1.03]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.33 (P = 0.74)						



Combo 04.01 depression measures (self-rated)

Review: BPD combination pharmacology-psychology
Comparison: 04 Depression measures
Outcome: 01 Self-rated measures (endpoint): combination treatments



Combo 04.02 depression measures (clinician-rated)

Review: BPD combination pharmacology-psychology
Comparison: 04 Depression measures
Outcome: 02 Clinician-rated measures (endpoint): combination treatments



Combo 05.01 global functioning measures

Review: BPD combination pharmacology-psychology
Comparison: 05 Global functioning measures
Outcome: 01 GAS/GAF



Combo 06.01 quality of life measures

Review: BPD combination pharmacology-psychology
Comparison: 06 Quality of life measures
Outcome: 01 Fluoxetine + IPT vs fluoxetine or fluoxetine + CT



Combo 07.01 self-harm/suicidality

Review: BPD combination pharmacology-psychology
Comparison: 07 Self-harm/suicidality
Outcome: 01 Self-harm/suicidality continuous measures



Combo 08.01 service use measures

Review: BPD combination pharmacology-psychology
Comparison: 08 Service use
Outcome: 01 Olanzapine + DBT vs placebo + DBT: Number of visits to emergency psychiatric services (12 weeks)

Study or sub-category	Treatment N	Treatment Mean (SD)	Control N	Control Mean (SD)	WMD (fixed) 95% CI	WMD (fixed) 95% CI
Soler2005 Olz+DBT	30	0.07(0.27)	30	0.03(0.20)		0.04 [-0.08, 0.16]
Total (95% CI)	30		30			0.04 [-0.08, 0.16]

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)

Combo 09.01 antidepressants: leaving treatment early for any reason

Review: BPD combination pharmacology-psychology
Comparison: 09 Leaving treatment early for any reason
Outcome: 01 Antidepressants (non-placebo comparisons)

Study or sub-category	Treatment n/N	Control n/N	RD (fixed) 95% CI	RD (fixed) 95% CI
01 Fluoxetine + DBT vs placebo + DBT				
Simpson 2004 Flx+DBT	3/12	2/13		0.10 [-0.22, 0.41]
Subtotal (95% CI)	12	13		0.10 [-0.22, 0.41]
Total events: 3 (Treatment), 2 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.60 (P = 0.55)				
02 Fluoxetine + IPT vs fluoxetine + CT				
Bellino2007 Flx+IPT	2/16	4/16		-0.13 [-0.39, 0.14]
Subtotal (95% CI)	16	16		-0.13 [-0.39, 0.14]
Total events: 2 (Treatment), 4 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.92 (P = 0.36)				
03 Fluoxetine + IPT vs fluoxetine				
Bellino2004 Flx+IPT	4/20	3/19		0.04 [-0.20, 0.28]
Subtotal (95% CI)	20	19		0.04 [-0.20, 0.28]
Total events: 4 (Treatment), 3 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.34 (P = 0.73)				



Combo 09.02 antipsychotics: leaving treatment early for any reason

Review: BPD combination pharmacology-psychology
Comparison: 09 Leaving treatment early for any reason
Outcome: 02 Antipsychotics (non-placebo comparisons)

Study or sub-category	Treatment n/N	Control n/N	RD (fixed) 95% CI	RD (fixed) 95% CI
03 Olanzapine + DBT vs placebo + DBT				
Soler2005 Olz+DBT	8/30	10/30		-0.07 [-0.30, 0.16]
Subtotal (95% CI)	30	30		-0.07 [-0.30, 0.16]
Total events: 8 (Treatment), 10 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.56 (P = 0.57)				



Combo 10.01 antidepressants: leaving treatment early due to side-effects

Review: BPD combination pharmacology-psychology
Comparison: 10 Leaving treatment early due to side-effects
Outcome: 01 Antidepressants (non-placebo comparisons)



Combo 10.02 antipsychotics: leaving treatment early due to side-effects

Review: BPD combination pharmacology-psychology
Comparison: 10 Leaving treatment early due to side-effects
Outcome: 02 Antipsychotics (non-placebo comparisons)



Combo 11.01 antidepressants: number of participants reporting side-effects

Review: BPD combination pharmacology-psychology
Comparison: 11 Number of participants reporting side effects
Outcome: 01 Antidepressants (non-placebo comparisons)



Combo 11.02 antipsychotics: number of participants reporting side-effects

Review: BPD combination pharmacology-psychology
Comparison: 11 Number of participants reporting side effects
Outcome: 02 Antipsychotics (non-placebo comparisons)

Study or sub-category	Treatment n/N	Control n/N	RD (fixed) 95% CI	RD (fixed) 95% CI
03 Olanzapine + DBT vs placebo + DBT				
Soler2005 Olz+DBT	0/30	0/30		0.00 [-0.06, 0.06]
Subtotal (95% CI)	30	30		0.00 [-0.06, 0.06]
Total events: 0 (Treatment), 0 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.00 (P = 1.00)				



Combo 12.01 antipsychotics: weight change

Review: BPD combination pharmacology-psychology
Comparison: 12 Side effects: weight or weight change (kg)
Outcome: 01 Antipsychotics

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	WMD (random) 95% CI	WMD (random) 95% CI
01 Olanzapine + DBT vs placebo + DBT						
Soler2005 Olz+DBT	30	2.74(3.20)	30	-0.05(2.39)		2.79 [1.36, 4.22]
Subtotal (95% CI)	30		30			2.79 [1.36, 4.22]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 3.83 (P = 0.0001)						



Combo 13.01 fluoxetine + IPT versus fluoxetine: efficacy measures

Review: BPD combination pharmacology-psychology
Comparison: 13 Fluoxetine + IPT versus fluoxetine
Outcome: 01 Efficacy measures

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Anxiety (Clinician-rated: HARS) (24 weeks)						
Bellino2004 Flx+IPT	16	11.00(4.40)	16	10.20(3.10)		0.20 [-0.49, 0.90]
Subtotal (95% CI)	16		16			0.20 [-0.49, 0.90]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.58 (P = 0.56)						
02 Depression (clinician-rated) HRSD (24 weeks)						
Bellino2004 Flx+IPT	16	9.10(3.00)	16	12.00(3.30)		-0.90 [-1.63, -0.16]
Subtotal (95% CI)	16		16			-0.90 [-1.63, -0.16]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.40 (P = 0.02)						



Combo 13.02 fluoxetine + IPT versus fluoxetine: quality of life measures

Review: BPD combination pharmacology-psychology
Comparison: 13 Fluoxetine + IPT versus fluoxetine
Outcome: 02 QOL: Fluoxetine vs fluoxetine + IPT

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 SAT-P physical (24 weeks)						
Bellino2004 Flx+IPT	16	62.80(11.90)	16	59.50(16.70)		0.22 [-0.47, 0.92]
Subtotal (95% CI)	16		16			0.22 [-0.47, 0.92]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.63 (P = 0.53)						
02 SAT-P psychological (24 weeks)						
Bellino2004 Flx+IPT	16	57.20(14.70)	16	69.00(11.70)		-0.87 [-1.59, -0.14]
Subtotal (95% CI)	16		16			-0.87 [-1.59, -0.14]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.33 (P = 0.02)						
03 SAT-P sleep, food, free time (24 weeks)						
Bellino2004 Flx+IPT	16	64.50(14.90)	16	56.40(20.70)		0.44 [-0.26, 1.14]
Subtotal (95% CI)	16		16			0.44 [-0.26, 1.14]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.22 (P = 0.22)						
04 SAT-P social functioning (24 weeks)						
Bellino2004 Flx+IPT	16	51.70(10.90)	16	68.50(12.50)		-1.40 [-2.18, -0.61]
Subtotal (95% CI)	16		16			-1.40 [-2.18, -0.61]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 3.49 (P = 0.0005)						
05 SAT-P work (24 weeks)						
Bellino2004 Flx+IPT	16	54.40(14.60)	16	56.00(31.20)		-0.06 [-0.76, 0.63]
Subtotal (95% CI)	16		16			-0.06 [-0.76, 0.63]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.18 (P = 0.86)						



Combo 13.03 fluoxetine + IPT versus fluoxetine: acceptability and tolerability measures

Review: BPD combination pharmacology-psychology
Comparison: 13 Fluoxetine + IPT versus fluoxetine
Outcome: 03 Tolerability and acceptability data

Study or sub-category	Treatment n/N	Control n/N	RD (fixed) 95% CI	RD (fixed) 95% CI
01 Leaving treatment early for any reason				
Bellino2004 Flx+IPT	4/20	3/19		0.04 [-0.20, 0.28]
Subtotal (95% CI)	20	19		0.04 [-0.20, 0.28]
Total events: 4 (Treatment), 3 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.34 (P = 0.73)				
02 Leaving treatment early due to side effects				
Bellino2004 Flx+IPT	0/19	0/20		0.00 [-0.09, 0.09]
Subtotal (95% CI)	19	20		0.00 [-0.09, 0.09]
Total events: 0 (Treatment), 0 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.00 (P = 1.00)				
03 Number of participants reporting side effects				
Bellino2004 Flx+IPT	0/19	0/20		0.00 [-0.09, 0.09]
Subtotal (95% CI)	19	20		0.00 [-0.09, 0.09]
Total events: 0 (Treatment), 0 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.00 (P = 1.00)				



Combo 14.01 fluoxetine + IPT versus fluoxetine + CT: efficacy measures

Review: BPD combination pharmacology-psychology
Comparison: 14 Fluoxetine + IPT versus fluoxetine + CT
Outcome: 01 Efficacy measures

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Anxiety (Clinician-rated: HARS) (24 weeks)						
Bellino2007 Flx+IPT	14	13.70(2.80)	12	12.50(1.10)		0.53 [-0.26, 1.32]
Subtotal (95% CI)	14		12			0.53 [-0.26, 1.32]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.32 (P = 0.19)						
02 Depression (clinician-rated) HRSD (24 weeks)						
Bellino2007 Flx+IPT	14	14.10(5.50)	12	13.70(5.70)		0.07 [-0.70, 0.84]
Subtotal (95% CI)	14		12			0.07 [-0.70, 0.84]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.18 (P = 0.86)						
03 Depression (self-rated) BDI (24 weeks)						
Bellino2007 Flx+IPT	14	15.70(4.50)	12	14.70(1.90)		0.27 [-0.50, 1.05]
Subtotal (95% CI)	14		12			0.27 [-0.50, 1.05]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.69 (P = 0.49)						



Combo 14.02 fluoxetine + IPT versus fluoxetine + CT: quality of life measures

Review: BPD combination pharmacology-psychology
Comparison: 14 Fluoxetine + IPT versus fluoxetine + CT
Outcome: 02 QOL: Fluoxetine vs fluoxetine + IPT + CT

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 SAT-P physical (24 weeks)						
Bellino2007 Flx+IPT	14	54.40(14.90)	12	60.00(7.70)		-0.45 [-1.23, 0.34]
Subtotal (95% CI)	14		12			-0.45 [-1.23, 0.34]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.12 (P = 0.26)						
02 SAT-P psychological (24 weeks)						
Bellino2007 Flx+IPT	14	56.10(15.40)	12	63.70(14.20)		-0.50 [-1.28, 0.29]
Subtotal (95% CI)	14		12			-0.50 [-1.28, 0.29]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.24 (P = 0.22)						
03 SAT-P sleep, food, free time (24 weeks)						
Bellino2007 Flx+IPT	14	53.10(8.80)	12	53.30(13.70)		-0.02 [-0.79, 0.75]
Subtotal (95% CI)	14		12			-0.02 [-0.79, 0.75]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.04 (P = 0.97)						
04 SAT-P social functioning (24 weeks)						
Bellino2007 Flx+IPT	14	70.00(12.80)	12	55.00(14.80)		1.06 [0.22, 1.89]
Subtotal (95% CI)	14		12			1.06 [0.22, 1.89]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.49 (P = 0.01)						
05 SAT-P work (24 weeks)						
Bellino2007 Flx+IPT	14	51.90(20.20)	12	39.20(10.20)		0.75 [-0.05, 1.55]
Subtotal (95% CI)	14		12			0.75 [-0.05, 1.55]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.83 (P = 0.07)						



Combo 14.03 fluoxetine + IPT versus fluoxetine + CT: acceptability and tolerability

Review: BPD combination pharmacology-psychology
Comparison: 14 Fluoxetine + IPT versus fluoxetine + CT
Outcome: 03 Tolerability and acceptability data



Combo 15.01 fluoxetine + DBT versus placebo: efficacy measures

Review: BPD combination pharmacology-psychology
Comparison: 15 Fluoxetine + DBT versus placebo
Outcome: 01 Efficacy measures



Combo 15.02 fluoxetine + DBT versus placebo: quality of life measures

Review: BPD combination pharmacology-psychology
Comparison: 15 Fluoxetine + DBT versus placebo
Outcome: 02 QOL: Fluoxetine vs fluoxetine + IPT

Study or sub-category	Treatment N	Treatment Mean (SD)	Control N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 SAT-P physical (24 weeks)						
Subtotal (95% CI)	0		0			Not estimable
Test for heterogeneity: not applicable						
Test for overall effect: not applicable						
02 SAT-P psychological (24 weeks)						
Subtotal (95% CI)	0		0			Not estimable
Test for heterogeneity: not applicable						
Test for overall effect: not applicable						
03 SAT-P sleep, food, free time (24 weeks)						
Subtotal (95% CI)	0		0			Not estimable
Test for heterogeneity: not applicable						
Test for overall effect: not applicable						
04 SAT-P social functioning (24 weeks)						
Subtotal (95% CI)	0		0			Not estimable
Test for heterogeneity: not applicable						
Test for overall effect: not applicable						
05 SAT-P work (24 weeks)						
Subtotal (95% CI)	0		0			Not estimable
Test for heterogeneity: not applicable						
Test for overall effect: not applicable						



Combo 15.03 fluoxetine + DBT versus placebo: acceptability and tolerability

Review: BPD combination pharmacology-psychology
Comparison: 15 Fluoxetine + DBT versus placebo
Outcome: 03 Tolerability and acceptability data

Study or sub-category	Treatment n/N	Control n/N	RD (fixed) 95% CI	RD (fixed) 95% CI
01 Leaving treatment early for any reason				
Simpson 2004 Flx+DBT	3/12	2/13		0.10 [-0.22, 0.41]
Subtotal (95% CI)	12	13		0.10 [-0.22, 0.41]
Total events: 3 (Treatment), 2 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.60 (P = 0.55)				
02 Leaving treatment early due to side effects				
Simpson 2004 Flx+DBT	0/12	0/13		0.00 [-0.14, 0.14]
Subtotal (95% CI)	12	13		0.00 [-0.14, 0.14]
Total events: 0 (Treatment), 0 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.00 (P = 1.00)				
03 Number of participants reporting side effects				
Simpson 2004 Flx+DBT	0/12	0/13		0.00 [-0.14, 0.14]
Subtotal (95% CI)	12	13		0.00 [-0.14, 0.14]
Total events: 0 (Treatment), 0 (Control)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.00 (P = 1.00)				



Combo 16.01 olanzapine + DBT versus placebo: efficacy measures

Review: BPD combination pharmacology-psychology
Comparison: 16 Olanzapine + DBT versus placebo
Outcome: 01 Efficacy measures

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Anxiety (Clinician-rated: HARS 12 weeks)						
Soler2005 Olz+DBT	30	18.43(5.94)	30	19.93(6.87)		-0.23 [-0.74, 0.28]
Subtotal (95% CI)	30		30			-0.23 [-0.74, 0.28]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.89 (P = 0.37)						
02 Depression (clinician-rated HRSD 12 weeks)						
Soler2005 Olz+DBT	30	13.71(5.46)	30	15.80(6.41)		-0.35 [-0.86, 0.16]
Subtotal (95% CI)	30		30			-0.35 [-0.86, 0.16]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.33 (P = 0.18)						
03 Self-harm/suicide attempts (12 weeks)						
Soler2005 Olz+DBT	30	1.23(2.87)	30	0.88(1.68)		0.15 [-0.36, 0.65]
Subtotal (95% CI)	30		30			0.15 [-0.36, 0.65]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.57 (P = 0.57)						



Combo 16.02 olanzapine + DBT versus placebo: service use measures

Review: BPD combination pharmacology-psychology
Comparison: 16 Olanzapine + DBT versus placebo
Outcome: 02 Service use

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Number of visits to emergency psychiatric services (12 weeks)						
Soler2005 Olz+DBT	30	0.07(0.27)	30	0.03(0.20)		0.17 [-0.34, 0.67]
Subtotal (95% CI)	30		30			0.17 [-0.34, 0.67]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.64 (P = 0.52)						



Combo 16.03 olanzapine + DBT versus placebo: acceptability and tolerability measures

Review: BPD combination pharmacology-psychology
Comparison: 16 Olanzapine + DBT versus placebo
Outcome: 03 Tolerability and acceptability data



Combo 16.04 olanzapine + DBT versus placebo: side-effects

Review: BPD combination pharmacology-psychology
Comparison: 16 Olanzapine + DBT versus placebo
Outcome: 04 Side-effects

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	WMD (random) 95% CI	WMD (random) 95% CI
01 Olanzapine + DBT vs placebo + DBT						
Soler2005 Olz+DBT	30	2.74(3.20)	30	-0.05(2.39)		2.79 [1.36, 4.22]
Subtotal (95% CI)	30		30			2.79 [1.36, 4.22]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 3.83 (P = 0.0001)